Pharmacotherapy of Inflammatory Bowel Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 23 November 2024 | Viewed by 197
Special Issue Editor
Interests: inflammatory bowel disease (IBD); Crohn´s disease; ulcerative colitis; controlled trials in IBD; observations in rare manifestations of IBD; pharmacological studies; studies on pathogenesis of IBD
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Successful treatment of Inflammatory Bowel Diseases (IBD) is characterised by two challenges: The wide range of miscellaneous clinical manifestations requiring individual therapeutic strategies and the permanent advent of novel therapeutic compounds. On grounds of ongoing scientific work in the pathogenesis of IBD, development of pharmacological immune modulation became a predominant target of research groups and the parmaceutical industy. Starting with classic immunosuppression the development of antibodies, oligonucelotides and recently also small molecules has substantially extended the range of pharmaceuticals for IBD. In addition, traditional drugs have gained new insights which make these products still valuable remedies for our daily clinical work.
Multifaceted new therapeutic options increase the chances for patients and physicians in the clinical setting. But this increase has to be accompanied by skill enhancement based on the scientific discussion as published by specialists in the field.
The aim of this Special Issue is to offer to our readers short but comprehensive and updated reviews on the conservative management of many manifestations of IBD.
Prof. Dr. Wolfgang Kruis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Treatment of Crohn's Disease
- treatment of ulcerative Colitis
- mesalazine for ulcerative colitis
- mesalazine for Crohn's Disease
- antibody strategies in IBD
- small molecules for IBD
- conservative managenment of Crohn's fistula
- therapy for extraintestinal manifestations
- new endpoints for treatment
